Literature DB >> 20332002

HTLV-1 p13, a small protein with a busy agenda.

Micol Silic-Benussi1, Roberta Biasiotto, Vibeke Andresen, Genoveffa Franchini, Donna M D'Agostino, Vincenzo Ciminale.   

Abstract

Human T-cell leukemia virus type 1 (HTLV-1) infection is characterized by life-long persistence of the virus in the host. While most infected individuals remain asymptomatic, 3-5% will eventually develop adult T-cell leukemia/lymphoma (ATLL) or tropical spastic paraparesis/HTLV-associated myelopathy (TSP/HAM) after a clinical latency that can span years (TSP/HAM) to decades (ATLL). The major oncogenic determinant among HTLV-1 proteins is the Tax transactivator, which influences the expression and function of a great number of cellular proteins, drives cell proliferation, reduces cell death, and induces genetic instability. The present review is focused on the current knowledge of p13, an HTLV-1 accessory protein targeted to the inner mitochondrial membrane and, under certain conditions, to the nucleus. In mitochondria, p13 produces an inward K+current that results in an increased production of ROS by mitochondria. These effects are linked to the protein's effects on cell turnover which include activation of primary T-cells and reduced proliferation/sensitization to death of tumor cells. Recent findings suggest that in the presence of Tax, p13 is subjected to ubiquitylation and partly targeted to the nucleus. Nuclear p13 binds Tax and inhibits its transcriptional activity. These findings suggest that the protein might exert distinct functions depending on its intracellular localization and influence both the turnover of infected cells and the balance between viral latency and productive infection.
Copyright © 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20332002      PMCID: PMC2941701          DOI: 10.1016/j.mam.2010.03.001

Source DB:  PubMed          Journal:  Mol Aspects Med        ISSN: 0098-2997


  43 in total

Review 1.  The p13II protein of HTLV type 1: comparison with mitochondrial proteins coded by other human viruses.

Authors:  D M D'Agostino; L Zotti; T Ferro; G Franchini; L Chieco-Bianchi; V Ciminale
Journal:  AIDS Res Hum Retroviruses       Date:  2000-11-01       Impact factor: 2.205

2.  Mitochondria, from cell death to proliferation.

Authors:  Pierre Rustin
Journal:  Nat Genet       Date:  2002-04       Impact factor: 38.330

3.  Thioredoxin-mediated redox control of human T cell lymphotropic virus type I (HTLV-I) gene expression.

Authors:  Tetsuro Sasada; Hajime Nakamura; Hiroshi Masutani; Shugo Ueda; Hiroshi Sono; Arimichi Takabayashi; Junji Yodoi
Journal:  Mol Immunol       Date:  2002-02       Impact factor: 4.407

4.  Activation of nuclear factor of activated T cells by human T-lymphotropic virus type 1 accessory protein p12(I).

Authors:  Björn Albrecht; Celine D D'Souza; Wei Ding; Susheela Tridandapani; K Mark Coggeshall; Michael D Lairmore
Journal:  J Virol       Date:  2002-04       Impact factor: 5.103

5.  Endoplasmic reticulum and cis-Golgi localization of human T-lymphotropic virus type 1 p12(I): association with calreticulin and calnexin.

Authors:  W Ding; B Albrecht; R Luo; W Zhang; J R Stanley; G C Newbound; M D Lairmore
Journal:  J Virol       Date:  2001-08       Impact factor: 5.103

6.  Autocrine antiapoptotic stimulation of cultured adult T-cell leukemia cells by overexpression of the chemokine I-309.

Authors:  T Ruckes; D Saul; J Van Snick; O Hermine; R Grassmann
Journal:  Blood       Date:  2001-08-15       Impact factor: 22.113

7.  Oncoviral bovine leukemia virus G4 and human T-cell leukemia virus type 1 p13(II) accessory proteins interact with farnesyl pyrophosphate synthetase.

Authors:  Laurent Lefèbvre; Alain Vanderplasschen; Vincenzo Ciminale; Hubertine Heremans; Olivier Dangoisse; Jean-Claude Jauniaux; Jean-François Toussaint; Vlado Zelnik; Arsène Burny; Richard Kettmann; Luc Willems
Journal:  J Virol       Date:  2002-02       Impact factor: 5.103

8.  Subcellular localization of the bovine leukemia virus R3 and G4 accessory proteins.

Authors:  Laurent Lefèbvre; Vincenzo Ciminale; Alain Vanderplasschen; Donna D'Agostino; Arsène Burny; Luc Willems; Richard Kettmann
Journal:  J Virol       Date:  2002-08       Impact factor: 5.103

9.  Transcription profile of cells infected with human T-cell leukemia virus type I compared with activated lymphocytes.

Authors:  Cynthia A Pise-Masison; Michael Radonovich; Renaud Mahieux; Pramita Chatterjee; Craig Whiteford; Janet Duvall; Claire Guillerm; Antoine Gessain; John N Brady
Journal:  Cancer Res       Date:  2002-06-15       Impact factor: 12.701

10.  Reduced levels of reactive oxygen species correlate with inhibition of apoptosis, rise in thioredoxin expression and increased bovine leukemia virus proviral loads.

Authors:  Amel Baya Bouzar; Mathieu Boxus; Arnaud Florins; Carole François; Michal Reichert; Luc Willems
Journal:  Retrovirology       Date:  2009-11-10       Impact factor: 4.602

View more
  25 in total

Review 1.  Viral proteins and Src family kinases: Mechanisms of pathogenicity from a "liaison dangereuse".

Authors:  Mario Angelo Pagano; Elena Tibaldi; Giorgio Palù; Anna Maria Brunati
Journal:  World J Virol       Date:  2013-05-12

Review 2.  Human T-lymphotropic virus proteins and post-translational modification pathways.

Authors:  Carlo Bidoia
Journal:  World J Virol       Date:  2012-08-12

3.  Small noncoding RNAs in cells transformed by human T-cell leukemia virus type 1: a role for a tRNA fragment as a primer for reverse transcriptase.

Authors:  Katia Ruggero; Alessandro Guffanti; Alberto Corradin; Varun Kumar Sharma; Gianluca De Bellis; Giorgio Corti; Angela Grassi; Paola Zanovello; Vincenzo Bronte; Vincenzo Ciminale; Donna M D'Agostino
Journal:  J Virol       Date:  2014-01-08       Impact factor: 5.103

4.  Suppression of HTLV-1 replication by Tax-mediated rerouting of the p13 viral protein to nuclear speckles.

Authors:  Vibeke Andresen; Cynthia A Pise-Masison; Uma Sinha-Datta; Marcia Bellon; Valerio Valeri; Robyn Washington Parks; Valentina Cecchinato; Risaku Fukumoto; Christophe Nicot; Genoveffa Franchini
Journal:  Blood       Date:  2011-06-15       Impact factor: 22.113

5.  High-yield production in E. coli and characterization of full-length functional p13II protein from human T-cell leukemia virus type 1.

Authors:  Elka R Georgieva; Peter P Borbat; Christina Fanouraki; Jack H Freed
Journal:  Protein Expr Purif       Date:  2020-04-30       Impact factor: 1.650

6.  Acetylation of the c-MYC oncoprotein is required for cooperation with the HTLV-1 p30(II) accessory protein and the induction of oncogenic cellular transformation by p30(II)/c-MYC.

Authors:  Megan M Romeo; Bookyung Ko; Janice Kim; Rebecca Brady; Hayley C Heatley; Jeffrey He; Carolyn K Harrod; Braden Barnett; Lee Ratner; Michael D Lairmore; Ernest Martinez; Bernhard Lüscher; Craig N Robson; Marie Henriksson; Robert Harrod
Journal:  Virology       Date:  2015-01-05       Impact factor: 3.616

7.  Functional implications of mitochondrial reactive oxygen species generated by oncogenic viruses.

Authors:  Young Bong Choi; Edward William Harhaj
Journal:  Front Biol (Beijing)       Date:  2014-12

Review 8.  Molecular biology of human T cell leukemia virus.

Authors:  Lee Ratner
Journal:  Semin Diagn Pathol       Date:  2019-04-16       Impact factor: 3.464

9.  Discovery and characterization of auxiliary proteins encoded by type 3 simian T-cell lymphotropic viruses.

Authors:  Jocelyn Turpin; Chloé Journo; Nga Ling Ko; Flore Sinet; Alexandre Carpentier; Amandine Galioot; Dustin Edwards; Anne-Mieke Vandamme; Louis Gazzolo; Madeleine Duc Dodon; Antoine Gessain; Fatah Kashanchi; Ivan Balansard; Romain Lacoste; Renaud Mahieux
Journal:  J Virol       Date:  2014-10-29       Impact factor: 5.103

10.  The 5' untranslated region of the human T-cell lymphotropic virus type 1 mRNA enables cap-independent translation initiation.

Authors:  Eduardo Olivares; Dori M Landry; C Joaquín Cáceres; Karla Pino; Federico Rossi; Camilo Navarrete; Juan Pablo Huidobro-Toro; Sunnie R Thompson; Marcelo López-Lastra
Journal:  J Virol       Date:  2014-03-12       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.